Next biotech runner...results imminenet, page-6

"The only thing with FTT its not a <10M MC like ANP or MEM - its already 60M so the 100-200% rise would be less likely right? "

It's late stage in an area of little competition. Their product, if successful, would actually save health authorities heaps - so it's commercially very attractive.

Also, if one looks at imu, their mkt cap is about $80m. But as they are on the verge of having perhaps the world's first cancer vaccine, their upside given good results is enormous.

It's not only about how low the mkt cap is, but the mkt cap to realistic near term possible mkt cap ratio that counts.

anp isn't a bad investment, but if imugene's cancer vaccine is successful then cancer vaccines are likely to become that standard treatment for 50% of all cancers. Hence anp could be working with a technology that could be superseded at a stroke.

ftt treatment has the potential to become the standard care for the current trial's target area, which is easily worth a mkt cap valuation of $300m imho. But it's also a real validation of the technology, so other indication possibilities command a higher valuation too.

So in short, if their mkt cap is going from $60m to $600m - that's 10x. So pretty good.

However if you are a gambling man imu could go from $80m to $8b - so that's 100x.

The trick is spread your eggs in both baskets, and some more besides.

ps. sorry for any cross promotion and also poor grammar in my last post (phones fault)